Toggle light / dark theme

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis.

The findings suggest—for the first time in a clinical trial—that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer’s dementia.

The study is published in The Lancet Neurology.

The warning came from one of the co-authors of the Space Weather Instrumentation, Measurement, Modelling and Risk (SWIMMR) S6 project group’s Severe space weather impacts on UK critical national infrastructure report, which was funded by the government.

The report said the government, regulators and CNI operators must “develop space weather preparedness plans” for CNI.

Space weather “is caused by disturbances from active regions of the Sun”, the report says.

This Viewpoint discusses how prerequisite comprehensive lifestyle interventions for novel antiobesity medications may disproportionately impact patients at highest risk of obesity-related complications and perpetuate disparities in care.